Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rabusertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 known ✓ | O14757 | 10/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.42 |
| ▸ | SRPK1 | Q96SB4 | 3/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 2/20 | 0.42 |
| ▸ | FLT4 | P35916 | 2/20 | 0.42 |
| ▸ | CLK2 | P49760 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.42 |
| ▸ | BRSK1 | Q8TDC3 | 2/20 | 0.42 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.42 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rabusertib SCHEMBL304748 | 1.00 | CHEK1 (1.00) | CHEK1FECHKCNH2RPS6KA3SRPK1 | |
| Rabusertib SCHEMBL30403507 | 1.00 | CHEK1 (1.00) | CHEK1FECHKCNH2RPS6KA3SRPK1 | |
| SCHEMBL14189549 | 0.93 | CHEK1 (0.86) | CHEK1FECHKCNH2RPS6KA3SRPK1 | |
| SCHEMBL305203 | 0.93 | CHEK1 (0.86) | CHEK1FECHKCNH2RPS6KA3SRPK1 | |
| SCHEMBL306054 | 0.90 | CHEK1 (0.82) | CHEK1FECHKCNH2RPS6KA3SRPK1 | |
| SCHEMBL305673 | 0.90 | CHEK1 (0.82) | CHEK1FECHKCNH2RPS6KA3SRPK1 | |
| SCHEMBL306053 | 0.90 | CHEK1 (0.82) | CHEK1FECHKCNH2RPS6KA3SRPK1 | |
| SCHEMBL305395 | 0.89 | CHEK1 (0.79) | CHEK1FECHKCNH2EPHA2ADRB2 | |
| SCHEMBL305112 | 0.89 | CHEK1 (0.79) | CHEK1FECHKCNH2EPHA2ADRB2 | |
| SCHEMBL305113 | 0.89 | CHEK1 (0.79) | CHEK1FECHKCNH2EPHA2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 597 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217307-A9 | METHODS FOR PREDICTING RESPONSE TO A RAS(ON) INHIBITOR AND COMBINATION THERAPIES | Revolution Medicines, Inc. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4448492-B1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE INC (US) | 2026-03-04 | — | — | EP | claimed |
| WO-2025217307-A1 | METHODS FOR PREDICTING RESPONSE TO A RAS(ON) INHIBITOR AND COMBINATION THERAPIES | Revolution Medicines, Inc. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| US-12404332-B2 | Methods for diagnosing and treating cancers | RESEARCH DEVELOPMENT FOUNDATION (US) | 2025-09-02 | — | — | US | claimed |
| US-20250262214-A1 | INTERMITTENT DOSING REGIMEN FOR AZENOSERTIB IN TREATING CANCER | ZENO MANAGEMENT, INC. | 2025-08-21 | — | — | US | claimed |
| WO-2025111339-A1 | TREATMENT OF CANCER WITH A PARG INHIBITOR | 858 THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250163456-A1 | AGENT FOR ENHANCING PRODUCTION OF VIRAL VECTOR AND METHOD FOR PRODUCING VIRAL VECTOR | NIPPON MEDICAL SCHOOL FOUNDATION (JP) | 2025-05-22 | — | — | US | claimed |
| US-20250134878-A1 | COMBINATION OF CHEK1 INHIBITOR AND TOP1 INHIBITOR FOR TREATING COLORECTAL CANCER | GENOME RESEARCH LIMITED (GB) | 2025-05-01 | — | — | US | claimed |
| CN-119746077-A | Use of ATR/Chk1 signaling pathway inhibitors to promote erythrocyte enucleation | 中国医学科学院基础医学研究所 | 2025-04-04 | — | — | CN | claimed |
| US-11304939-B2 | Methods for treating oral cancers | CHANG GUNG UNIVERSITY (TW) | 2022-04-19 | — | — | US | claimed |
| US-10744141-B2 | Compositions and methods for treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-08-18 | — | — | US | claimed |
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY | 2018-07-05 | — | — | US | claimed |
| EP-3313819-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Case Western Reserve University (US) | 2018-05-02 | — | — | EP | claimed |
| WO-2016210134-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-12-29 | — | — | WO | claimed |
| US-20160252530-A1 | AGENT FOR PREVENTING OR TREATING SPINOCEREBELLAR ATAXIA | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2016-09-01 | — | — | US | claimed |
| EP-3056210-A1 | DRUG FOR PREVENTION OR TREATMENT OF SPINOCEREBELLAR DEGENERATION | National University Corporation Tokyo Medical and Dental University (JP) | 2016-08-17 | — | — | EP | claimed |
| US-8093244-B2 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2012-01-10 | — | — | US | claimed |
| EP-1869020-B1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORP (US) | 2010-12-01 | — | — | EP | claimed |
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2009-06-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | PPP2CA, PPP3CA, PPP4C | CHEK1 178/4885FECH 3200/4885KCNH2 4752/4885 |
| US-10744141-B2 | Compositions and methods for treating cancer | PPP2CA, PPP3CA, PPP4C | CHEK1 178/4885FECH 3200/4885KCNH2 4752/4885 |
| US-20250134878-A1 | COMBINATION OF CHEK1 INHIBITOR AND TOP1 INHIBITOR FOR TREATING COLORECTAL CANCER | TOP1, CHEK1, CHEK2 | CHEK1 2/4885FECH 997/4885KCNH2 4545/4885 |
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | CHEK1, CHEK2, PCNA | CHEK1 1/4885FECH 2006/4885KCNH2 3943/4885 |
| US-12404332-B2 | Methods for diagnosing and treating cancers | CHEK1, CHEK2, MRE11 | CHEK1 1/4885FECH 1846/4885KCNH2 4241/4885 |
| US-20250262214-A1 | INTERMITTENT DOSING REGIMEN FOR AZENOSERTIB IN TREATING CANCER | ABL1, KRAS, JAK2 | CHEK1 7/4885FECH 4361/4885KCNH2 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.